Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie


Sign up for our daily newsletter


U.S. FDA panel backs Paladin Labs’ parasitic disease drug

2:50 pm by | 0 Comments

(Reuters) - Paladin Labs Inc's experimental drug to treat a rare parasitic disease is safe and effective enough to be approved, an advisory panel to the U.S. Food and Drug Administration said on Friday.

The drug, Impavido, is designed to treat three forms of leishmaniasis, a disease caused by a group of parasites known as Leishmania, which are spread by the bite of a female sand-fly.

The FDA is not bound to follow its advisory panel's advice but typically does so.

(Reporting by Toni Clarke in Washington; Editing by Gerald E. McCormick)

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement